Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: A retrospective analysis

被引:51
|
作者
Katyal, S
Oliver, JH
Peterson, MS
Chang, PJ
Baron, RL
Carr, BI
机构
[1] Univ Pittsburgh, Med Ctr, Dept Radiol, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Med Ctr, Dept Transplantat Med, Pittsburgh, PA 15213 USA
关键词
D O I
10.2214/ajr.175.6.1751665
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE. The purpose of this study was to use hepatic arterial phase helical CT to as sess tumor vascularity and predict the likelihood of response to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. MATERIALS AND METHODS. Helical CT findings for 57 patients with hepatocellular carcinoma were classified into one of three patterns of vascularity on the basis of the degree of tumor or liver enhancement during the hepatic arterial phase. Cases in which hypervascular lesions predominated were classified as a type 1 pattern. Cases in which hypovascular lesions predominated were classified as a type 2 pattern. Patients were classified as responders or nonresponders on the basis of the changes of tumor size revealed on CT after three transcatheter arterial chemoembolization treatments. RESULTS. We classified the 57 patients as 37 responders (65%) and 20 nonresponders (35%). A statistically significant correlation between the type 1 hypervascular pattern and response to transcatheter arterial chemoembolization was seen; conversely, the type 2 hypovascular pattern correlated with nonresponse to transcatheter arterial chemoembolization (chi-square = 7.85, p = 0.02). Patients classified as responders lived significantly longer than those classified as nonresponders with 12-, 24-, and 36-month survival rates of 90%, 67%, and 36%. respectively, for responders and 70%, 17%, and 10%, respectively, for nonresponders. CONCLUSION. We found that patients who responded to transcatheter arterial chemoembolization had prolonged survival (p < 0.01). Response correlated closely with tumor vascularity as shown on hepatic arterial phase helical CT.
引用
收藏
页码:1665 / 1672
页数:8
相关论文
共 50 条
  • [41] Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma
    Imai, Yukinori
    Chikayama, Taku
    Nakazawa, Manabu
    Watanabe, Kazuhiro
    Ando, Satsuki
    Mizuno, Yoshie
    Yoshino, Kiyoko
    Sugawara, Kayoko
    Hamaoka, Kazuhiro
    Fujimori, Kenji
    Inao, Mie
    Nakayama, Nobuaki
    Oka, Masashi
    Nagoshi, Sumiko
    Mochida, Satoshi
    JOURNAL OF GASTROENTEROLOGY, 2012, 47 (02) : 179 - 186
  • [42] Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma
    Fan, J
    Tang, ZY
    Yu, YQ
    Wu, ZQ
    Ma, ZC
    Zhou, XD
    Zhou, J
    Qiu, SJ
    Lu, JZ
    DIGESTIVE SURGERY, 1998, 15 (06) : 674 - 678
  • [43] The effect of additional local radiotherapy after transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma
    Shim, S
    Seong, J
    Han, K
    Chon, C
    Lee, J
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S417 - S417
  • [44] Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma
    Yukinori Imai
    Taku Chikayama
    Manabu Nakazawa
    Kazuhiro Watanabe
    Satsuki Ando
    Yoshie Mizuno
    Kiyoko Yoshino
    Kayoko Sugawara
    Kazuhiro Hamaoka
    Kenji Fujimori
    Mie Inao
    Nobuaki Nakayama
    Masashi Oka
    Sumiko Nagoshi
    Satoshi Mochida
    Journal of Gastroenterology, 2012, 47 : 179 - 186
  • [45] Transcatheter arterial infusion chemotherapy with cisplatin in combination with transcatheter arterial chemoembolization decreases intrahepatic distant recurrence of unresectable hepatocellular carcinoma
    Kawabe, Naoto
    Hashimoto, Senju
    Nakano, Takuji
    Nakaoka, Kazunori
    Fukui, Aiko
    Yoshioka, Kentaro
    JGH OPEN, 2021, 5 (06): : 705 - 711
  • [46] The clinical safety and efficacy of conventional transcatheter arterial chemoembolization and drug-eluting beads-transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A meta-analysis
    Han, Tao
    Yang, Xiaodan
    Zhang, Yue
    Li, Gao
    Liu, Lu
    Chen, Tingsong
    Zheng, Zhendong
    BIOSCIENCE TRENDS, 2019, 13 (05) : 374 - 381
  • [47] Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma
    Rong-Ce Zhao
    Jing Zhou
    Yong-Gang Wei
    Fei Liu
    Ke-Fei Chen
    Qiu Li
    Bo Li
    Hepatobiliary&PancreaticDiseasesInternational, 2017, 16 (05) : 493 - 498
  • [48] Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis
    Xie, Feng
    Zang, Jiajie
    Guo, Xiaojing
    Xu, Feng
    Shen, Rongxi
    Yan, Long
    Yang, Jiamei
    He, Jia
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (03) : 455 - 462
  • [49] Therapeutic Response Assessment of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: Ultrasonography, CT and MR Imaging
    Minami, Yasunori
    Kudo, Masatoshi
    ONCOLOGY, 2013, 84 : 58 - 63
  • [50] Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
    Meng, Mao-Bin
    Cui, Yao-Li
    Lu, You
    She, Bin
    Chen, Yan
    Guan, Yong-Song
    Zhang, Rui-Ming
    RADIOTHERAPY AND ONCOLOGY, 2009, 92 (02) : 184 - 194